Can we cure bullous skin diseases?

Area of Science:

• Immunology
• Dermatology
• Autoimmune Diseases

Background:

• Autoimmune bullous diseases (AIBDs) like pemphigus and pemphigoid involve autoantibodies against structural proteins, leading to blistering and morbidity.
• Current treatments (glucocorticoids, immunomodulators, biologics) have limitations, including high relapse rates and adverse effects, hindering sustained remission.

Purpose of the Study:

• To review the pathophysiology of AIBDs, focusing on immune mechanisms.
• To analyze limitations of existing therapies.
• To explore emerging curative treatment options and preventive strategies.

Main Methods:

• Review of current literature on AIBD pathophysiology and treatments.
• Analysis of emerging immunotherapies: CAR-T therapy, regulatory T cell interventions, tolerogenic vaccines.
• Consideration of preventive measures like genetic screening and environmental risk management.

Main Results:

• AIBD pathophysiology involves autoreactive B and T cells, inflammation, and immune dysregulation.
• Existing treatments often fail to provide lasting remission.
• Emerging therapies show promise for curative approaches.

Conclusions:

• A three-step approach (disease control, pathogenic cell elimination, immune tolerance induction) is proposed for AIBD management.
• Novel immunotherapies and immune modulation techniques may lead to sustained remission and potential cures for AIBDs.
• Integrating prevention strategies is crucial for long-term AIBD management.